Dietary patterns and blood biomarkers in healthy aging. Key takeaways. * A study of 1,769 adults aged 60+ found that adherence to Mediterranean and anti-inflammatory diets correlates with improved metabolic and brain health markers. * Higher scores on healthy eating indices were linked to increased folic acid levels and reduced concentrations of GDF15, a protein associated with cellular stress and aging. * While the study identifies significant associations, it highlights that existing chronic conditions may influence the relationship between nutrition and biological aging markers. TrendPulse analysis. Industry context. This research arrives at a pivotal moment for the **functional food** and **longevity** sectors. TrendPulse is witnessing a shift from broad "healthy eating" advice toward precision nutrition, where consumers and clinicians alike are looking for objective, data-driven validation of dietary interventions. The identification of biomarkers like **GDF15** - which acts as a proxy for cellular stress - is becoming a standard metric in the growing field of geroscience, where companies are increasingly looking to quantify the "biological age" of their customers. Competitors in the supplement and personalized nutrition space, such as **Zoe** or **InsideTracker**, are already capitalizing on this trend by offering direct-to-consumer blood testing that maps dietary intake to specific metabolic markers. This study reinforces the validity of their business models, suggesting that the market is moving away from generic wellness claims toward measurable, evidence-based outcomes. The industry is essentially moving toward a "biomarker-first" approach, where the efficacy of a nutritional product is measured by its ability to modulate specific proteins or inflammatory markers in the blood. Why this matters. For executives and investors, this study underscores the rising demand for "nutraceuticals" that can demonstrate a tangible impact on biological aging. As the global population ages, the economic burden of age-related chronic disease is driving a massive pivot toward preventative health. Companies that can bridge the gap between dietary habits and clinical blood markers will likely capture the largest share of the longevity market. The data suggests that the "Mediterranean" blueprint remains the gold standard, but the future lies in personalizing these diets based on individual inflammatory profiles. Furthermore, the regulatory landscape is likely to tighten around health claims. As we gain the ability to measure the impact of diet on markers like **TNFRSF1B** or **alkaline phosphatase**, regulators may eventually demand more rigorous proof for functional food claims. Decision-makers should prioritize R&D investments that focus on longitudinal data collection. Understanding how specific food groups mitigate cellular stress markers like GDF15 provides a strategic advantage in developing products that are not just "healthy," but clinically relevant for the aging demographic. The bottom line. Nutritional interventions are increasingly being validated by specific blood biomarkers, signaling a transition toward a data-driven, precision-based longevity market where measurable biological outcomes define product success. Read the full article. This analysis is based on reporting from MindBodyGreen AI-powered news analysis · September 29, 2026 Editorially Reviewed

ZOE's Gut Check - Part 1 | Is Daily30+ a pivot from personalization or an accessible entry point? Nlumn Nsights Vol 4. Issue 5 Is Daily30+ a pivot from personalization or an accessible entry point? ZOE helped bring personalized nutrition into the mainstream by showing that people can respond differently to the same foods. But as the company refocuses on gut health and scales Daily30+, a plant-based gut health supplement intended for a broad audience, their strategy raises an important category question: is ZOE moving away from personalization, or using a simpler product as the first rung of a personalized nutrition ladder? For companies interested in personalized nutrition, ZOE is a useful case study. Its journey highlights both the power and the limits of science-led differentiation. Scientific credibility can build trust, attract investors, and create a compelling brand story. But when a product moves onto the supplement shelf or into Amazon search results, science has to compete with price, claims, reviews, convenience, distribution, and consumer habits. The shift: from high-touch personalization to scalable gut health. ZOE began broadening beyond its classic test-led model in summer 2024 with the launch of Daily30+. By March 2026, ZOE had formally launched ZOE 2.0, an app-first membership that no longer requires cookies, blood-fat testing, or continuous glucose monitoring, while keeping gut microbiome testing as an optional add-on. Daily30+ is a key component of the strategic shift. It is a30+ plant-based supplement positioned around gut health, plant diversity, fiber, and daily nutritional support. ZOE says Daily30+ was designed by its scientists and that the company ran a randomized controlled trial on the original formulation, with findings presented at the Nutrition Society Congress2024 and in a paper (ZOEDaily30+ evidence). ZOE's strategy shift appears to be less about abandoning personalization and more about changing the economics of how personalization is delivered. The original model was scientifically strong but commercially demanding. It created a strong scientific point of difference, but it also limited how quickly and affordably ZOE could scale. Available information suggests ZOE is trying to make its business more accessible, recurring, and easier to scale. At the turn of 2025,ZOE cut its U.K. monthly membership price by about 60%. The Grocer reported that ZOE's total revenue fell from £66.1m to £34.1m for the year ending August 2025, and that membership revenue fell from £27.7m to £17.4m. ZOE attributed the year-over-year revenue change to a "one-off strategic move" to make the app substantially more affordable. The public evidence does not prove that the original deep-phenotyping model was unprofitable. But the business signals suggest ZOE is reducing onboarding cost and complexity, lowering the entry price, creating more value through app membership, using AI to replace some measured testing, and addingDaily30+ as a recurring daily product. The strategic goal appears to be preservingZOE's scientific reputation moat while making the consumer experience more affordable, more habitual, and more scalable. Why gut health may be the right entry point. Gut health may be one of the strongest parts of ZOE's strategy because it narrows the consumer need. Personalized nutrition can become too broad. If a company tries to personalize everything, from energy, immunity, sleep, weight, mood, fitness, women's health, longevity, blood sugar, inflammation, and digestive health all at once, the proposition can become diffuse and expensive to deliver. Gut health gives ZOE a clearer point of entry because it is a meaningful consumer benefit and scientifically connected to ZOE's strengths. That makes gut health a two-fold strategy shift. ZOE needed a simpler, more affordable entry point, and gut health is a consumer need that the company can credibly support with its science, data, and product ecosystem.It links naturally to food recommendations, products like Daily30+, and can ladder to microbiome testing and future product innovation. ZOE's Crowdcube materials explicitly position the company around a gut health revolution, with three core revenue products: app membership, an at-home gut health test, and Daily30+ subscriptions. The same materials state that over 70% of revenue from June to August 2025 came from recurring subscription-based memberships, and that Daily30+ had more than23,000 monthly subscribers by August 2025 (ZOE Crowdcube pitch). Thus, gut health isn't just a claims platform. It's part of a refocused strategy to better align with a key consumer need. The question is whether ZOE can turn that focus into a defensible ecosystem rather than a single supplement brand. Daily30+ as the first rung of a personalization ladder. Daily30+ creates strategic tension. ZOE's founding science says people are different, while Daily30+ suggests many people can benefit from the same daily product. That can look like a contradiction. It may also be a funnel strategy: use a simple gut-health product to bring more consumers into the ZOE ecosystem, then move a subset toward deeper engagement, testing, and personalized guidance. Many consumers are interested in gut health, but they may not be ready to start with a test, wait for results, or pay for a full personalized nutrition program. Daily30+ gives ZOE a simpler, more affordable, easier-to-understand first step. ZOE already has several components of a tiered system: * a large content and education platform * a daily supplement * an app-based membership * AI food tracking and meal feedback * a gut health test * microbiome data infrastructure * personalized nutrition advice * future potential to connect data, products, and behavior change ZOE's current membership page describes an app and gut health test offering that includes AI-enabled food tracking, personalized food advice, mindful eating tools, a gut health test, meal scores, personalized insights, and gut microbiome feedback. It also continues to underscore ZOE's data-driven approach. ZOE states that the app is powered by data from more than 300,000microbiome DNA tests and that the gut health test provides deeper personalization in the app (ZOE membership). In that context, Daily30+ may be designed to build trust, create a daily habit, and make ZOE more accessible and affordable. The challenge is conversion. ZOE must show that Daily30+ is not just a standalone supplement, but a meaningful first step into a broader personalized nutrition journey. The business will depend on whether ZOE can move consumers from product trial to app engagement, from app engagement to gut testing, and from gut testing to sustained behavior change. Nlumn's perspective. Supplements can support scale, but they can also pull a company into a noisy market where differentiation becomes harder to defend. ZOE may be making the right strategic move by focusing on gut health, simplifying the test experience, and using Daily30+ as an accessible entry point. The open question is execution: can ZOE convert a broad supplement purchase into personalized solutions, including app engagement, test adoption, and personalized behavior change before the product becomes lost in the crowded gut-health supplement market? The Care/of lesson is that personalization cannot become athin wrapper around supplements. ZOE's opportunity is to avoid that trap bykeeping Daily30+ connected to a broader gut-health system: app, test, data,feedback, behavior change, and measurable outcomes. If ZOE can do that,Daily30+ becomes an entry point into personalized nutrition. If it cannot, itrisks becoming another science-backed supplement competing in a crowdedmarketplace where claims, price, reviews, and convenience can overwhelm thescience. Talk to Nlumn. Ready to get started? Have questions? Contact Nlumn for a free consultation.